2-208248388-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_005896.4(IDH1):c.395G>A(p.Arg132His) variant causes a missense change. The variant allele was found at a frequency of 0.00000992 in 1,613,530 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R132C) has been classified as Pathogenic.
Frequency
Consequence
NM_005896.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IDH1 | NM_005896.4 | c.395G>A | p.Arg132His | missense_variant | Exon 4 of 10 | ENST00000345146.7 | NP_005887.2 | |
IDH1 | NM_001282386.1 | c.395G>A | p.Arg132His | missense_variant | Exon 4 of 10 | NP_001269315.1 | ||
IDH1 | NM_001282387.1 | c.395G>A | p.Arg132His | missense_variant | Exon 4 of 10 | NP_001269316.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151806Hom.: 0 Cov.: 33
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461724Hom.: 0 Cov.: 32 AF XY: 0.0000138 AC XY: 10AN XY: 727172
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151806Hom.: 0 Cov.: 33 AF XY: 0.0000270 AC XY: 2AN XY: 74100
ClinVar
Submissions by phenotype
not provided Pathogenic:3
- -
IDH1: PS4, PM1, PM2, PP4, PS3:Supporting -
An IDH1 c.395G>A (p.Arg132His) variant was identified at a near heterozygous allelic fraction of 43.4%, a frequency which may be consistent with germline origin. This variant has been reported in a germline state in individuals with Ollier disease and gliomas (Kendroud S et al., Neurology, 92; Number 15_supplement April 9, 2019; Ikeda H et al., PMID: 36942363). It has also been reported in a somatic state in individuals with Ollier disease and Maffucci syndrome (Ashirov N et al., PMID: 37374260; Pansuriya TC et al., PMID: 22057234) and in numerous types of cancer in the cancer database COSMIC (Genomic mutation ID: COSV61615239). It has been reported in the ClinVar database as a germline pathogenic variant by six submitters (ClinVar Variation ID: 156444). The IDH1 c.395G>A (p.Arg132His) variant is only observed on 16/1,613,530 alleles in the general population (gnomAD v4.1.0), indicating it is not a common variant. This variant resides within a region of IDH1 that is defined as a critical functional domain (Reitman ZJ et al., PMID: 20513808). Computational predictors indicate that the variant is damaging, evidence that correlates with impact to IDH1 function. In support of this prediction, functional studies using cell lines show that this variant alters the enzymatic properties of IDH1 and results in a gain-of-function for NADPH-dependent reduction of alpha-ketoglutarate (Dang L et al., PMID: 19935646). Other variants in the same codon, c.394C>T (p.Arg132Cys), c.394C>A (p.Arg132Ser) and c.395G>T (p.Arg132Leu) have been reported and are considered pathogenic (Saiji E et al., PMID: 31240473; Amary MF et al., PMID: 22057236; ClinVar variation ID's: 375891, 375893, 375889). Based on available information and the ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), this variant is classified as pathogenic. -
Glioma susceptibility 1 Pathogenic:2
- -
- -
Enchondromatosis Pathogenic:2
- -
- -
Metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria Pathogenic:1
This variant has been previously reported as a mosaic change in patients with metaphyseal chondromatosis and elevated D-2-hydroxyglutaric aciduria (PMID: 24049096, 22025298). It is absent from the gnomAD population databases and thus is presumed to be rare. The c.395G>A, p.Arg132H variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. The p.Arg132H variant results in loss of its native enzymatic activity and gain of alternative enzymatic activity (producing D-2-hydroxyglutarate) (PMID 21446021). Structural studies demonstrated that when p.Arg132 is mutated to histidine (R132H), residues in the active site are shifted to produce structural changes consistent with reduced oxidative decarboxylation of isocitrate and acquisition of the ability to convert alpha-ketoglutarate to 2HG (PMID 19935646). Excess accumulation of 2HG has been shown to lead to an elevated risk of malignant brain tumors in patients with inborn errors of 2HG metabolism (PMID 18931888). Based on the available evidence, the c.395G>A, p.Arg132H variant is classified as Pathogenic. -
Metaphyseal chondromatosis Pathogenic:1
PS4, PM2, PM5, PM6_Strong, PP3 -
Glioblastoma multiforme, somatic Pathogenic:1
- -
Neoplasm Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at